1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Innovation1 Biotech Inc.

Innovation1 Biotech Inc.

IVBT
Innovation1 Biotech Inc.US flagOther OTC
0.00
USD
- -
- -
4,494.00Market Cap
Innovation1 Biotech Inc.
IVBT
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
TTM
FRC
- -
- -
- -
0.04
0.18
- -
0.02
- -
- -
- -
Revenue per Share
- -
-0.2
-0.2
-2.4
-0.39
-8.59
5.53
-2.73
-0.7
-0.29
Basic EPS, GAAP
- -
-0.08
-0.33
-1.1
-1.79
-1.37
-0.16
-0.21
-0.03
-0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
-0.15
-2.12
-2.47
-12.8
-15.81
-2.92
-2.9
-2.8
Book Value per Share
- -
-0.26
-0.39
0.41
0.05
-8.95
-1.22
-2.64
-0.17
-0.16
Tangible Book Value per Share
3
- -
- -
- -
- -
- -
- -
15
20
21
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
-2,600.43
-790.87
-18,363.84
-7,759.45
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
-1
- -
-3
1
-41
-6
-5
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-5,816.73
-214.61
-218,464.69
33,764.03
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
-3
- -
-30
-3
-3
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
LT Debt
- -
- -
- -
- -
- -
-3
- -
3
-3
-3
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
-43.41
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Aug'23
Nov'24
Feb'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
20
22
22
Market Capitalization
17
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Aug'23
Nov'24
Feb'24
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
3
3
3
Payables & Accruals
3
3
3
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-2,027.51%
-220.24%
Free Cash Flow
- -
2,010.62%
-80.19%
Net Income, GAAP
- -
-584.39%
-85.35%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
1,056.53%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.07
-0.09
-0.09
- -
-2.73
2023
-0.04
-0.4
-0.03
- -
-0.7
2024
-0.02
-0.02
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
NervGen Pharma Corp. Common stock (NGEN)
Hemostemix Inc (HMTXF)
AlzeCure Pharma AB (ALZCUR.ST)
Oxurion N.V. (TBGNF)
Transgene S.A. (TRGNF)
Proteina Co., Ltd. (468530.KQ)
Business
Innovation1 Biotech Inc. (IVBT) develops and commercializes innovative biopharmaceutical products focused on targeted therapies for oncology and rare genetic disorders; its core offerings include small-molecule inhibitors under the InnoTarget brand, monoclonal antibodies for immunotherapy, and gene-editing platforms utilizing proprietary CRISPR-based technologies; the company also provides contract research services for preclinical drug discovery and clinical trial support. Headquartered in San Diego, California, Innovation1 Biotech was founded in 2018 and operates primarily in North America with expanding clinical trial sites in Europe and Asia, targeting pharmaceutical companies, research institutions, and healthcare providers in the biotech sector. In 2025, the company announced a strategic partnership with a leading global CRO for accelerated Phase II trials of its lead oncology candidate, secured a $75 million Series C funding round led by venture capital firms specializing in biotech innovation, and launched a new service division for AI-driven drug design tools.